Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

mprop="name">Kouros Motamed, Chulho Park and Catherine Cheng.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. 

More information is available at www.sorrentotherapeutics.com.

About IGDRASOL

IGDRASOL's lead therapeutic platform is Cynviloq™, a branded micellar paclitaxel formulation which is free of cremophor and human serum albumin, the excipients for Taxol® (cremophor-based paclitaxel) and albumin-bound paclitaxel (Abraxane®), respectively. Cynviloq™ combines the simplicity of manufacturing and preparation of Taxol® and potentially the albumin-mediated transport of paclitaxel. IGDRASOL intends to conduct registration trials for multiple cancer indications.  

The executives of IGDRASOL are a group of pharmaceutical veterans who believe that personalized paclitaxel nanoparticle therapy will present a paradigm shift in the delivery of chemotherapeutic agents.  To learn more about IGDRASOL's mission, please visit its website (http://www.igdrasol.com).

'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2
... as Marker of,Treatment Success -, SAN FRANCISCO, ... presented at the 59th Annual Meeting of,the American ... shows that,PEGASYS(R) (peginterferon alfa-2a) treatment regimens result in ... patients as,compared to regimens with another pegylated interferon.(1), ...
... Denmark, October 31 , - DoctorConsult in ... Improve Clinician Decision Making and Health Care Business,Performance, ... and more than a,century of experience as a ... provide interactive clinical reference and clinical decision,support (CDS) ...
Cached Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
(Date:2/27/2015)... Wisconsin (PRWEB) February 27, 2015 Dr. ... plastic surgeons , is pleased to announce the expansion ... now open in Delafield. Quintessa has begun seeing patients ... the new Delafield location will offer a variety of ... including: Botox, filler injectables, micro laser peels, chemical peels, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 On February 24 ... Real Liquid Botox ,” that details the development of ... is working its way through FDA trials. For those afraid ... cream is very attractive. Of course, if the drug ultimately ... at a physician’s office. (see: goo.gl/PQvQwk) , “As the article ...
(Date:2/27/2015)... Beach, FL (PRWEB) February 27, 2015 ... medical companies, devices and pharmaceuticals, Benedict Advertising & ... as its newest client. The company’s patented NITROUSEAL® ... a pain-free, no-stress method of sedation. , Sedation ... medical patient comfort to a new level, though ...
(Date:2/27/2015)... February 27, 2015 The winter season is ... and expansion. When mold grows, it can be harmful to ... to avoid the consequences of mold growth with the help ... is offering tips on the best ways to prevent mold ... which makes perfect conditions for mold to thrive. Mold must ...
(Date:2/27/2015)... 2015 Victorian Hotel recently celebrated Valentine’s ... who wanted to spend the auspicious day together. This ... a jump on Valentine’s Day with a sweet overnight ... of their luxurious rooms. , The hotel started ... for a mouthwatering 3 course meal at Café 335. ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Is Topical Botox the Next Big Thing? 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2
... of asthma-causing immune molecules Asthma and ... Soluble IgE molecules, produced by immune cells known as ... Therapeutic targeting of IgE in the blood can neutralize ... allergic asthma. However, this approach does not halt IgE ...
... was worse than physical abuse alone, study found , MONDAY, ... finds that older women who are exposed to physical and ... twist did show up in the results, study author Dr. ... more damaging than physical abuse alone. , Why? "The physical ...
... be wise, expert says, , MONDAY, May 10 (HealthDay ... its authors describe as a precise description of the ... heart-related fats. , It provides "the best evidence yet ... blood lipids profile," said Dr. Joan Sabate, who chairs ...
... ... Beard & Arsenault in Louisiana says the estimated 5,000 U.S. deaths each year from ... the most part preventable.” , ... Alexandria, LA (PRWEB) May 10, 2010 – Louisiana’s Department of Health and ...
... - The Massachusetts Eye and Ear Infirmary, Harvard Medical ... renewal from the National Institutes of Health, National Eye ... scientists to promote translational and clinical research into cures ... five-year K12 grant to Mass. Eye and Ear (representing ...
... ... ... E. Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical ... Lipscomb University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn ...
Cached Medicine News:Health News:JCI online early table of contents: May 17, 2010 2Health News:JCI online early table of contents: May 17, 2010 3Health News:JCI online early table of contents: May 17, 2010 4Health News:JCI online early table of contents: May 17, 2010 5Health News:JCI online early table of contents: May 17, 2010 6Health News:JCI online early table of contents: May 17, 2010 7Health News:JCI online early table of contents: May 17, 2010 8Health News:Older, Abused Women Suffer Poor Mental Health 2Health News:Eating Nuts May Help Cholesterol Levels 2Health News:Eating Nuts May Help Cholesterol Levels 3Health News:Food Poisoning Suspected in 3 Deaths, 40 Illnesses at Central State Hospital in Pineville, LA 2Health News:Mass. Eye and Ear receives NEI grant renewal for 'growing' clinical/scientists 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Classic proven design with superior clinical results...
... Using high-performance materials contributes to ... addition to surgical procedures and technique, ... great bearing on your patients' outcomes, ... DePuy developed MARATHON Cross-Linked Polyethylene. MARATHON ...
Medicine Products: